Marißen J, Haiß A, Meyer C, et al. Efficacy of Bifidobacterium animalis subsp. lactis (BB-12), B. infantis and Lactobacillus acidophilus (La-5) probiotics to prevent gut dysbiosis in preterm infants of 28+0–32+6 weeks of gestation: a randomised, placebo-controlled, double-blind, multicentre trial: the PRIMAL Clinical Study protocol. BMJ Open 2019;9:e032617. doi:10.1136/ bmjopen-2019-032617.
This article was previously published with errors. The published article has been revised with below corrections:
1. ‘Bifidobacterium longum’ has been updated as ‘Bifidobacterium animalis subsp. lactis’ in the article title, ‘Method and analysis’ of the ABSTRACT, 'Strengths and limitations of this study’ section and in the last paragraph of the INTRODUCTION section.
2. The beginning statements in ‘Intervention and comparator’ of the METHOD AND ANALYSIS has been updated as ‘The probiotic formulation (verum), consisting of B. species and L. acidophilus corresponds to the formulation that has been most commonly used among the participating study sites in the past.20 The active intervention is provided once daily in single dose capsules. Each dose contains 1.5×109 colony forming units (CFUs) of each of the strains: Lactobacillus acidophilus, Bifidobacterium animalis subsp. lactis and B. infantis.’